eCTD Module 4 Structure: Nonclinical Study Reports Guide

Why Module 4 Structure Matters

Module 4 is not usually read as one long book. Reviewers move between the nonclinical overviews in Module 2, the study reports in Module 4, and labeling or clinical context elsewhere in the application. The structure should make that movement easy.

A weak Module 4 package creates practical problems:

• Study identifiers differ between Module 2 and Module 4.
• A toxicology finding is summarized in Module 2 but hard to locate in the report.
• GLP status is unclear.
• A pivotal nonclinical report is placed under the wrong subsection.
• Literature references are mixed with internal study reports.
• A report version differs from the one used in the nonclinical summary.

These issues slow review and can make the nonclinical safety story less credible.

What Is eCTD Module 4?

eCTD Module 4 contains nonclinical study reports. It is the detailed evidence layer for pharmacology, pharmacokinetics, and toxicology studies.

Module 2.4 and 2.6 summarize nonclinical information, but Module 4 contains the study reports and supporting references.

Reviewers should be able to use Module 4 to understand:

• The nonclinical testing program
• Study design and methods
• Test article, dose levels, route, duration, and species
• Results and toxicological findings
• GLP status where applicable
• How nonclinical findings support clinical use and labeling

eCTD Module 4 Section Structure

The structure is based on ICH M4S. It is intended to be common across regions.

How Module 4 Connects to Module 2

Module 4 contains full reports. Module 2.4 and 2.6 summarize and interpret those reports. The two modules should be reviewed together.

Check that:

• Study titles and identifiers match.
• Species, dose levels, route, and duration match.
• NOAEL, exposure, safety margin, and key finding statements match.
• GLP status is described consistently.
• Important adverse findings are not omitted from summaries.
• Literature references are cited consistently.
• The nonclinical conclusions support the proposed clinical plan or labeling.

Module 2 should not overstate what Module 4 proves. Module 4 should make the detailed evidence easy to find when the reviewer follows the summary.

Section 4.2.1: Pharmacology

Pharmacology study reports generally address the product's biological or pharmacological activity.

Common structure areas include:

• Primary pharmacodynamics
• Secondary pharmacodynamics
• Safety pharmacology
• Pharmacodynamic drug interactions

These reports support the intended pharmacologic effect and help identify risks relevant to first-in-human or later clinical development.

Section 4.2.2: Pharmacokinetics

Pharmacokinetics reports address absorption, distribution, metabolism, and excretion, often called ADME.

Common structure areas include:

• Analytical methods and validation reports
• Absorption studies
• Distribution studies
• Metabolism studies
• Excretion studies
• Pharmacokinetic drug interaction studies
• Other pharmacokinetic studies

These reports help reviewers understand exposure, metabolism, accumulation, and species relevance.

Section 4.2.3: Toxicology

Toxicology reports address safety findings from nonclinical testing.

Common structure areas include:

• Single-dose toxicity
• Repeat-dose toxicity
• Genotoxicity
• Carcinogenicity
• Reproductive and developmental toxicity
• Local tolerance
• Other toxicity studies

The exact content depends on the product, route, duration, clinical plan, and applicable ICH guidance.

Study Report Placement

Placement should follow the scientific purpose of the report. If a study includes multiple endpoints, place it where the primary purpose belongs and cross-reference as appropriate.

Examples:

• A primary pharmacodynamic model usually belongs in 4.2.1.
• ADME and exposure studies usually belong in 4.2.2.
• Repeat-dose toxicity studies usually belong in 4.2.3.
• Safety pharmacology should be placed under the applicable pharmacology subsection.
• Literature references should stay in 4.3 unless they are part of a submitted study report package.

Do not use Module 4 as a loose repository for all preclinical files. The structure should make it clear which evidence supports pharmacology, exposure, and toxicity conclusions.

Module 4 Readiness Checklist

Before filing, confirm:

• The Module 4 table of contents reflects all submitted reports.
• Study titles, numbers, and report dates match Module 2.
• GLP status is clear where applicable.
• Final reports, not draft versions, are submitted unless justified by context.
• Key toxicology findings are reflected in Module 2.4 and 2.6.
• Safety pharmacology and toxicology reports are in the correct subsections.
• Literature references are separated from study reports.
• Cross-references to Module 2 and labeling are accurate.
• Important limitations or deviations are not hidden.

This checklist helps the team avoid a common late-stage problem: the reports are present, but the submission narrative and report package do not line up.

Common Module 4 Structure Errors

Module 4 structure should make the nonclinical evidence easy to trace from overview to summary to full report.

Nonclinical Findings and Labeling

Module 4 does not contain labeling, but it can support labeling decisions. Toxicology, reproductive toxicity, genotoxicity, carcinogenicity, local tolerance, and safety pharmacology findings may affect warnings, precautions, pregnancy/lactation language, dosing limitations, monitoring, or clinical risk-management language.

Before finalizing Module 4, check whether important nonclinical findings are also reflected in:

• Module 2.4 nonclinical overview
• Module 2.6 nonclinical summaries
• Module 2.5 clinical overview where relevant
• Proposed labeling
• Investigator brochure or risk documents, where applicable

The goal is consistency. Reviewers should not find a major nonclinical concern in a study report that is missing from the sponsor's interpretation.

When a Study Is Not Included

Not every product will have every possible nonclinical study type, but the absence of expected studies should be understood and supported by the development rationale. The submission should not leave reviewers guessing whether a study is missing, not applicable, waived, scientifically unnecessary, or located somewhere else.

For each expected nonclinical category, confirm:

• Whether the study was conducted
• Whether the report is included
• Whether a scientific rationale explains why it is not needed
• Whether the rationale is reflected in Module 2
• Whether labeling, clinical planning, or risk language depends on the study

This is especially important for areas such as reproductive toxicity, genotoxicity, carcinogenicity, safety pharmacology, local tolerance, and specialized toxicity studies, where expectations depend on product type, route, duration, population, and development stage.

How Assyro Supports Module 4 Readiness

Assyro helps teams compare Module 4 reports against Module 2.4 and 2.6 summaries, safety conclusions, labeling support, and cross-references. eCTD Validation, eCTD Authoring, and Regulatory Gap Analysis can help catch missing reports, mismatched study titles, inconsistent findings, and stale summary language before submission.

For Module 4, the value is nonclinical traceability: the summaries and study reports should support the same safety story.

References

*This guide reflects FDA and ICH eCTD structure information current as of May 2026. Confirm current ICH M4S guidance, FDA submission standards, and product-specific nonclinical expectations before filing.*